Merck Provides Update on Phase III Clinical Program for Preladenant, the Company’s Investigational Parkinson’s Disease Medicine

Dateline City: 

WHITEHOUSE STATION, N.J.

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today provided an update on the clinical program for preladenant,
Merck’s investigational adenosine A2A receptor antagonist for
the treatment of Parkinson’s disease (PD). An initial review of data
from three separate Phase III trials did not provide evidence of
efficacy for preladenant compared with placebo.

Language: 

English

Contact HTML: 

MerckMedia Contacts:Pam Eisele, 908-423-5042orClaire Mulhearn, 908-423-7425orInvestor Contacts:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088

Ticker Slug: 

Ticker: MRK Exchange: NYSE

read more

Source: Merck.com - Research and Development News - May 23, 2013 Category: Pharmaceuticals Authors: hq_site_admin Tags: Research and Development News Corporate News Latest News Source Type: news